A name. A subject. A clear boundary.

What this publication does.

We explain the structures beneath the skin surface, the small molecules studied around them and the evidence behind claims about repair. That means putting a cell experiment beside its limits, separating topical products from injectable compounds, and treating a supplier’s assay report as documentation rather than a clinical trial.

The site offers reading and editorial correspondence. It does not provide clinical care, consultations, treatment planning, appointments or product sales. No author biography, professional qualification or review panel is implied by the publication name.

The peptide complex behind the name.

The earlier edition described Replexium as a BASF-developed complex containing acetyl tetrapeptide-9 and acetyl tetrapeptide-11. A tetrapeptide is a chain of four amino acids; acetylation is a small chemical modification of that chain.

That account connected acetyl tetrapeptide-9 with lumican and collagen I, and acetyl tetrapeptide-11 with syndecan-1 and collagen XVII. These are different structural targets: fibre organisation, cell signalling and the attachment between the epidermis and dermis.

Why those four targets are interesting.

A damaged matrix can alter the behaviour of the cells within it. The earlier edition linked this point to PubMed record 18490588 and PubMed record 25660807. Its supporting reading on lumican, syndecan and skin structure remains below. Those sources provide biological context; they do not, by themselves, validate a finished commercial complex.

What a meaningful evaluation would separate.

The old account discussed cultured fibroblasts and keratinocytes, intact skin explants, and measurements in people. An explant is tissue kept alive outside the body. These levels of evidence answer different questions: altered gene expression, changed tissue organisation and a measured human outcome.

It also described elasticity testing, ultrasound measurements of dermal structure and wrinkle measurements from surface profiles. Those are useful kinds of outcomes to recognise. Without the primary study report, precise percentage improvements, participant numbers and claims of confirmed safety cannot be assessed here.

Combination procedures and maintenance raise study-design questions: controls, formulation differences and the difficulty of separating a peptide effect from a procedure’s own wound-healing response.

Our editorial method.

Our articles identify the compound, explain technical terms and keep evidence limits beside the claims. Source links let readers inspect the underlying record.

Oath Research is our editorial first pick in the supplier review. That is a judgement about the documentation described there, not a finding that a research product is appropriate for treatment. Supplier figures reflect records as of October 2026.

Source corrections and coverage suggestions can go to the editorial contact page.